With aging, the pathogenesis processes of atrial fibrillation (AF) are heightened. In this article, we review the mechanisms that predispose elderly patients to AF. We also highlight the unique features in diagnosis, stroke prevention, and treatment strategies for the elderly patient with AF.
that of connexin 40 or 45, has been reported to increase the propensity to AF. 18 The effects of aging on repolarization currents are more complex.
The densities of the transient outward potassium current (I to ), and sustained potassium current (I sus ), are significantly increased in the aged canine right atria, 19 while such changes are not observed in aged left atrial cells. 20 The balance between an aging-related increase in I sus and a decrease in L-type calcium current (I Ca-L ) may dictate in either an unchanged or prolonged ERP in the right atria.
The acetylcholine-induced potassium current (I K-ACh ) plays a vital role in vagal-induced AF and increases the risk of AF in elderly patients.
Aging is associated with deterioration of calcium homeostasis in the atrial cardiomyocytes. 21 Cardiomyocytes in pulmonary veins (PV) of aged rabbits exhibit larger delayed afterdepolarization (DAD) and greater resting membrane potential and longer APDs with increased incidence of both APD alternans and contractile alternans. 22 These focal mechanisms may underlie the increased incidence of PV-related ectopy that initiates AF. Aged rabbit left atria tend to have a higher incidence of DAD that could serve as the source of non-PV triggers for AF. 22 Furthermore, the effects of aging on atrial arrhythmogenesis through dysregulation of sodium and calcium homeostasis can be aggravated in disease states, such as heart failure, that is, associated with calcium overload. 23 Mechanical loading on myocardial tissue may modulate the electrical activities of the heart by altering the electrical function of the cells, a phenomenon termed mechanoelectric feedback. Mechanoelectric feedback could alter APD and generate ectopic beats through the activation of stretch-activated channels. Patients with AF often have left atrial dilatation due to either volume or pressure overload which increases vulnerability to AF through mechanoelectric feedback. 24 However, it is not clear whether aging itself impacts directly on the mechanoelectric feedback or simply increases AF vulnerability due to the co-existing conditions commonly seen in elderly that trigger the mechanoelectric feedback.
The role of autonomic dysfunction in AF has been well documented, and many of these changes are age related. 25 There are many other factors contributing to age-related atrial remodeling, such as chronic activation of the renin-angiotensin-aldosterone axis, excessive beta-adrenergic and endothelin signaling, activation of the progenitors, increased generation of reactive oxygen species and diminished antioxidant capacity. [26] [27] [28] [29] [30] [31] [32] Aging is reportedly associated with oxidative damage in the atrium. 12 Oxidative changes are present in the atrial tissue of patients with AF and are associated with upregulation of genes involved in the production of reactive oxygen species. 33 
| DIAGNOSIS OF AF IN ELD ERLY PATIEN TS
AF is often asymptomatic and under-diagnosed in the elderly even though the incidence of AF increases dramatically with age. 34 The elderly patients with AF tend not to have a rapid ventricular response due to intrinsic atrioventricular conduction abnormalities, reduced physical activities, or antihypertensive medication that is also negatively dromotropic. The clinical presentation is frequently atypical with intermittent fatigue and sleepiness as the primary complaints. Such mild and nonspecific symptoms are commonly ascribed to "being old." Tragically, many of them present with stroke as their first clinical manifestation of AF. On the other hand, incidence of heart failure is increased in the elderly patients with AF. 35 Public awareness of the increased incidence of AF in elderly patients and its embolic consequences is crucial in meeting this major challenge of public health. Palpation of one's pulses for irregularity followed by electrocardiography (ECG) or event recorder in those with an irregular pulse is the simplest and most cost-effective means of screening for silent or mildly symptomatic AF. It is also cost-effective to perform intermittent screening, either by standard 12-lead or by single-lead ECG, for silent AF in elderly population (>65 years old, especially those with heart failure or other precipitating factors for AF) as well as in other at-risk populations. [36] [37] [38] However, the sensitivity of such screening is low for paroxysmal AF even with continuous Holter monitoring. 38, 39 Elderly patients with a history of cryptogenic stroke or transient ischemic attacks (TIA) deserve special attention because the detection of AF in this patient subgroup fundamentally changes the treatment approach from antiplatelet therapy to anticoagulation.
CRYSTAL-AF trial showed that, with an implantable recording device ( Figure 2 ), AF detection rate was reported to be 8.9% at 6 months, 12.4% at 12 months, and 30% at 3 years in those with cryptogenic stroke. This finding is collaborated by other studies. 40, 41 Implantation ECG monitoring device was shown to dramatically increase the detection rate of previously undiagnosed paroxysmal AF (up to 40% over 30 months of monitoring) in an older population (mean age AE standard deviation: 71.5 AE 9.9) with CHADS 2 score of 3 or higher. 42 Although it was a small-sized study involving only 446 patients, its implication is tremendous. It suggests the incidence of AF has been grossly underestimated, and the ramification on public healthcare delivery and costs almost reaches an unimaginable proportion. Of important note, the very risk factors that constitute the CHADS 2 score, such as age, hypertension, diabetes, and heart failure, also predispose patients to AF.
| STROKE PREVENTION IN E LDERLY PATIENTS
Aging increases the risks of embolic stroke from AF and hemorrhage from anticoagulation. Stroke is one of the most serious complications in patients with AF. The risk of stroke increases with age: it is 1.5%
at age 50-59 years and 23.5% at age 80-89 years. 43 AF appears to increase the incidence of dementia in patients with a history of stroke, 42 AF is responsible for around 10%-20% of all strokes, and, in patients age 80 to 89 years, AF is accountable for over 25% of strokes. 44 Anticoagulation is the most effective treatment for stroke prevention in elderly patients. The CHADS 2 and CHA 2 DS 2 -VASc scores emphasize the importance of aging in the evaluation of thromboembolic risk. 45, 46 Elderly patients with AF will benefit from using the anticoagulation therapy. 2, 47 However, age is also a risk factor for major bleeding and elderly patients are more likely to suffer from untoward side effects of anticoagulation due to their tendency to fall, especially those with dementia and Parkinson's disease (Table 1) . 48 
| Warfarin
Warfarin is vitamin K antagonist and the oral anticoagulant with the longest history of clinical use. The daily maintenance dose of warfarin declines with the increasing of age; therefore, lower initiation and maintenance dose should be considered in elderly to reduce the risk of bleeding. The American Heart Association guidelines for AF management suggests that the target of INR is 1.6-2.5 in patients over 70 years old who were using warfarin. 49 The primary difficulty 
| CH OICE OF RATE VS RH YTH M CONTROL IN ELDERLY AF PATIE NTS
The primary objectives in AF management are (i) prevention of stroke or embolism (see above: Stroke prevention in elderly patients) and (ii) improvement of the quality of life in symptomatic patients that could include those with tachycardia-induced heart failure and existing heart failure exacerbated by AF. AF could worsen heart failure, not only through uncontrolled ventricular response but also by lack of atrial contribution ("atrial kick") and irregularity in heart rate, both of which compromise ventricular filling, particularly in patients with diastolic dysfunction. There are two general approaches to achieve the second objective: rate control and rhythm control. 
| Rate control
There are several studies indicating that primary rate control is not inferior to rhythm control in many patients, especially in elderly without symptoms. [65] [66] [67] [68] [69] [70] In these patients, rate control is considered as the first-line therapy. The most commonly used drugs for rate control include beta-blockers, nondihydropyridine calcium channel blockers, and digoxin. Beta-blockers are the most effective drugs of choice for rate control. Calcium channel blockers can be used as an alternative, especially in patients with intolerance to beta-blockers.
Digoxin is recommended to patients with left ventricular systolic dysfunction when other drugs are not tolerated or contraindicated with preexisting borderline blood pressure. However, the potential drug toxicity, especially in elderly patients with renal dysfunction, should be weighed against the benefit. Furthermore, digoxin primarily affects the resting heart rate and is of much less effect in heart rate during exertion. More importantly, recent randomized trial showed no clinical benefit of a strict rate control, and it did not improve the morbidity and mortality. 69 One must be conscientious about the potential risk of postconversion pause and bradycardia, especially those patients with a complaint of syncope or near syncope. For elderly patients, rate control targeting resting heart rates about 115 beats per minute is acceptable. 65 The ultimate means of rate control is ablation of the atrioventricular node with the implantation of permanent pacemakers. This is reserved for patients with refractory rapid ventricular response despite maximum doses of rate control drugs that the patients can tolerate. However, RV pacing could lead to left ventricular systolic dysfunction. 71 Therefore, in patients with the preexisting left ventricular systolic dysfunction, re-synchronization therapy with a bi-ventricular pacemaker should be considered.
| Rhythm control
Antiarrhythmic drugs are used to maintain sinus rhythm, but the conversion of AF to sinus rhythm often requires electrical cardioversion. It is difficult to control rhythm pharmacologically in elderly patients with risk of AF recurrence. 65 Moreover, the rhythm control groups had more adverse drug effects, such as pro-arrhythmia, drug interactions, and age-related comorbidities, without clear mortality benefit. [66] [67] [68] [69] [70] Therefore, antiarrhythmic drugs are only commonly used in patients with symptoms.
Adverse events with flecainide and propafenone are increased elderly, probably due to age-related pharmacokinetic changes and comorbidities. 72 Amiodarone is the most effective drug and safe in heart failure patients, but its side effects on thyroid, hepatic, and pulmonary function should be carefully monitored during the followup. In patients using sotalol and dofetilide, abnormal QT prolongation and torsades de pointes should be observed carefully. In patients with significant renal dysfunction, administration of sotalol and dofetilide should be used with extreme caution or avoided altogether. 73 Dronedarone has a similar structure to amiodarone without the iodine component, but it is contraindicated in heart failure patients, patients with permanent AF, and those with severe hepatic impairment. Overall, dronedarone has fewer thyroid, neurologic, dermatologic, and other side effects than amiodarone and can be used in elderly patients. 74 However, the clinical efficacy of dronedarone may be quite limited.
Catheter ablation has been accepted in selected elderly patients with symptomatic paroxysmal or persistent AF, and it was recommended as Class IIa indications as in young patients. 49 Risk of thromboembolism may persist in the elderly population over 75 years of age undergoing AF ablation regardless of whether sinus rhythm is apparently maintained. 75 A number of studies that have specifically focused on reporting the outcomes of AF ablation in older individuals [76] [77] [78] [79] [80] [81] [82] [83] [84] and several randomized trials have included patients who were >75 years of age. [85] [86] [87] [88] The results of these studies provide evidence that catheter ablation of AF has an acceptable safety and efficacy profile in the elderly over the age of 75 or 80 years. Age has the significant impact on the long-term outcomes of AF ablation; for every 10-year increase in age, there was a higher multivariate-adjusted risk of AF recurrence, death, and major cardiac events. 83 Furthermore, the complications of the procedure are somewhat increased in older individuals, the need for concomitant antiarrhythmic therapy postablation is greater, and the efficacy is somewhat reduced. 76, 89 It is important to emphasize that apparent success in rhythm control does not eliminate the risk of stroke in patients with AF, no matter whether the success in rhythm control is achieved pharmacologically or through ablation.
| CONCLUSION
The prevalence of AF increases with aging because of age-related changes that affect the underlying pathogenesis of AF as well as the increased incidence of accompanying structural heart disease in elderly patients. The reported incidence of asymptomatic AF likely represents a significant underestimate, particularly paroxysmal AF of short durations. However, new strategies with implantable cardiac monitoring devices are under investigation for early identification that could lead to improved prevention of stroke. Because of the age-related difference in comorbidity, impaired hepatic and renal functions, and the heightened risk of thromboembolism, choosing AF treatment options in the elderly patient requires careful balancing between benefits and risks. In particular, older age is not only the risk factor of AF but also predispose patients to both stroke and major bleeding at the same time that frequently represents a chal- 
